Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 402 participants.
Also called NCT01346865
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 402 participants
- Registry
-
NCT01346865
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Terminated
Technical summary
Registry record NCT01346865. Randomized; double masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2015-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Cilostazol
- Intervention (Drug)
- Placebo
- Lead sponsor
- Seung-Jung Park
- Collaborator
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Record details
- Record id
cardio:ct-nct01346865- Content hash
63dd3ff8c9fcd6fb86af72a07e8bcad7c9696272aec34c2f49f8e05e4d74be62